Results 21 to 30 of about 3,115 (154)

Association of Ebtifibatide Administration Timing and TIMI Flow of Infarct Related Artery During Primary PCI

Majalah Kardiologi Indonesia, 2013
Background. Optimal administration timing of Glicoprotein IIb/IIIa inhibitor in STEMI patients undergoing Primary PCI is controversial. Several stud -ies have shown that early administration of eptifibatide, which is given to patients with pain awitan of
Abdul Hakim Alkatiri, Yoga Yuniadi, Dicky A Hanafy, Doni Firman, Sunarya Soerianata   +4 more
doaj   +1 more source

How safe is eptifibatide during urgent carotid artery stenting?

Frontiers in Neurology, 2013
Background: Glycoprotein IIB/IIIA inhibitors are occasionally utilized during carotid artery stenting (CAS) in the presence or absence of a visualized intra-operative thrombus. Objective: We assess the hemorrhagic and clinical outcomes associated with
Hesham eAllam, Nirav eVora, Randall eEdgell, Richard Charles Callison, Yasir eAl Khalili, Michelle eStorkan, Amer eAlshekhlee, Amer eAlshekhlee   +7 more
doaj   +1 more source

Antiplatelet agents’-ticagrelol and eptifibatide-safety in experimental colitis in mice

The Turkish Journal of Gastroenterology, 2020
Background/Aims: To evaluate the side effects of two antiplatelet agents - ticagrelor and eptifibatide - in mice with experimentally-induced inflammatory bowel disease. Methods and Material: This study was designed as a controlled, animal, drug safety
Stanko S. Petrovic, Milijana M. Vasiljevska, Slobodan D. Obradovic, Dino K. Tarabar, Radoje B. Doder, Ivana J. Majstorovic, Marijana D. Petrovic, Zvonko M. Magic, Bojana M. Cikota, Nenad J. Perisic, Irina A. Brcerevic, Nebojsa S. Manojlovic, Nemanja K. Rancic   +12 more
doaj   +1 more source

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017
BackgroundIn patients with non‐ST‐segment elevation acute coronary syndromes, inhibition of platelet aggregation (IPA) with a potent P2Y12 inhibitor, ticagrelor, was inferior to tirofiban infusion at 2 hours, indicating that glycoprotein IIb/IIIa ...
Moazez J. Marian, Oluseun Alli, Firas Al Solaiman, Brigitta C. Brott, Mark Sasse, Tara Leesar, Sumanth D. Prabhu, Massoud A. Leesar   +7 more
doaj   +1 more source

Design of termo-sensitive molecularly imprinted polymers(MIP) and in vitro evaluation of controlled release of Eptifibatide drug [PDF]

شیمی کاربردی روز
In this research, a nano polymer was fabricated via the molecular imprinted polymer (MINP) method to transport and control the release of the drug eptifibatide.
Sharif Kaamyabi, Negar Karimi Hajishoreh, Abolfazl Akbarzadeh   +2 more
doaj   +1 more source

Cryo-EM structures of full-length integrin αIIbβ3 in native lipids

Nature Communications, 2023
Platelet integrin αIIbβ3 is maintained in a bent inactive state (low affinity to physiologic ligand), but can rapidly switch to a ligand-competent (high-affinity) state in response to intracellular signals (“inside-out” activation).
Brian D. Adair, Jian-Ping Xiong, Mark Yeager, M. Amin Arnaout   +3 more
doaj   +1 more source

Venom‐Derived Bioactive Peptides: From Toxins to Therapeutics

Advanced Therapeutics, Volume 9, Issue 8, August 2026.
Venomics → Target Identification → Peptide Optimization → Therapeutic Translation Bioactive venom peptides targeting ion channels, enzymes, and receptors drive the development of next‐generation precision therapeutics. ABSTRACT Venoms are complex biochemical mixtures composed of diverse bioactive components, including proteins, enzymes, small molecules,
Eldho Sabu, Othman Al Musaimi
wiley   +1 more source

A Therapeutic Dilemma: Catastrophic ST‐Elevation Myocardial Infarction Following Antiplatelet Therapy Interruption in a Patient With JAK2‐Positive Polycythemia Vera

Clinical Case Reports, Volume 14, Issue 8, August 2026.
Premature interruption of dual antiplatelet therapy in a patient with polycythemia vera and clinically suspected acquired von Willebrand syndrome triggered catastrophic recurrent stent thrombosis, whereas perioperative bridging with eptifibatide enabled safe surgery. ABSTRACT Polycythemia vera is associated with a thrombotic–hemorrhagic paradox.
Behrouz zarei, Amirhossein Rezaei Latifi, Mohammad Salari   +2 more
wiley   +1 more source

A woman with eptifibatide (integrilin)‐induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review

Clinical Case Reports
Eptifibatide, a GPIIb/IIIa receptor inhibitor, has shown its efficacy and safety in patients with high clot burden in their coronary vessels. It is widely used in patients with this condition.
Morteza Safi, Roozbeh Nazari, Nahid Senobari, Homa Taheri, Pouya Ebrahimi   +4 more
doaj   +1 more source

Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital

Journal of Research in Pharmacy Practice
Objective: This cross-sectional descriptive study was conducted over 3 months (April–June 2025) among acute coronary syndrome (ACS) patients who received eptifibatide at Shahid Chamran Hospital, Isfahan.
Javad Amini, Mehrnoush Dianatkhah, Mahnaz Momenzadeh, Saeide Bahrani, Ehsan Shirvani, Niloufar Sadat Mirasi, Ali Heidarnezhad   +6 more
doaj   +1 more source